---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-190873"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2022-07-11T23:59:59+00:00"
generated_at: "2026-06-24T17:36:51.888317+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics reports positive Phase 2a data for PLN-74809 in IPF; FVC and QLF improved

## Summary
- INTEGRIS-IPF Phase 2a met primary and secondary endpoints; PLN-74809 well tolerated with no drug-related SAEs or discontinuations.
- Pooled PLN-74809 showed 80% reduction in FVC decline vs placebo (-15.1 mL vs -74.1 mL); 80 mg dose showed +24.6 mL FVC increase from baseline.
- Dose-dependent reduction in ≥10% FVCpp decline: 18.2% (40mg), 8.7% (80mg), 4.5% (160mg) vs 17.4% placebo.
- QLF imaging showed dose-dependent antifibrotic effect; 160 mg group showed 0.00% mean change vs 1.15% placebo.
- Company to discuss data with regulators; 320 mg cohort data expected early 2023.

## SEC filing metadata
- accession: 0001193125-22-190873
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2022-07-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000119312522190873/0001193125-22-190873-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000119312522190873/d356984d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-190873
- JSON: https://secwatch.observer/filing/0001193125-22-190873.json
- Plain text: https://secwatch.observer/filing/0001193125-22-190873.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.